Therapeutic strategies for castration-resistant prostate cancer are limited, and the emergence of neuroendocrine differentiation in CRPC patients as a result of treatment with second generation of AR pathway inhibitors poses significant clinical challenges. The gene discussed is AR; the disease is Familial prostate cancer.